ES2083353T3 - Sistema infectivo de liberacion de farmacos. - Google Patents
Sistema infectivo de liberacion de farmacos.Info
- Publication number
- ES2083353T3 ES2083353T3 ES87303651T ES87303651T ES2083353T3 ES 2083353 T3 ES2083353 T3 ES 2083353T3 ES 87303651 T ES87303651 T ES 87303651T ES 87303651 T ES87303651 T ES 87303651T ES 2083353 T3 ES2083353 T3 ES 2083353T3
- Authority
- ES
- Spain
- Prior art keywords
- drug release
- release system
- infective drug
- retrovirus
- serve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
UN VIRION DE SUMINISTRO DE FARMACOS QUE CONTIENE UN SISTEMA DE EXPRESION PARA EL INGREDIENTE ACTIVO DE LA PROTEINA DESEADA EMPAQUETADO EN UNA ENVUELTA DERIVADA DE UN RETROVIRUS RESULTA ESPECIALMENTE UTIL EN EL SUMINISTROO DE MATERIALES QUE NECESITAN CRUZAR MEMBRANAS CELULARES PARA REALIZAR SU FUNCION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85586586A | 1986-04-24 | 1986-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2083353T3 true ES2083353T3 (es) | 1996-04-16 |
Family
ID=25322287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES87303651T Expired - Lifetime ES2083353T3 (es) | 1986-04-24 | 1987-04-24 | Sistema infectivo de liberacion de farmacos. |
Country Status (9)
Country | Link |
---|---|
US (2) | US5652130A (es) |
EP (1) | EP0243204B1 (es) |
JP (2) | JP2773833B2 (es) |
AT (1) | ATE133449T1 (es) |
CA (1) | CA1310924C (es) |
DE (1) | DE3751682T2 (es) |
ES (1) | ES2083353T3 (es) |
GR (1) | GR3019460T3 (es) |
HK (1) | HK38497A (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662896A (en) * | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US6133029A (en) * | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
JPH03504079A (ja) * | 1988-03-21 | 1991-09-12 | カイロン コーポレイション | 組換えレトロウィルス |
US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US6241982B1 (en) | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
DE3990262T1 (de) * | 1988-03-21 | 1991-04-04 | Viagene Inc | Rekombinante retroviren |
ATE219519T1 (de) * | 1989-01-23 | 2002-07-15 | Chiron Corp | Rekombinanttherapien für infektionen und hyperproliferative störungen |
EP0832980B1 (en) * | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
WO1990012087A1 (en) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Infectious targetted replication-defective virion |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
ATE199398T1 (de) * | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
ES2091916T3 (es) * | 1989-12-21 | 1996-11-16 | Whitehead Biomedical Inst | Metodo para suministrar moleculas en el interior de celulas eucarioticas. |
US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
US5817491A (en) * | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
JP3547129B2 (ja) * | 1991-02-19 | 2004-07-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 変更宿主域を有するウィルス粒子 |
CA2117303C (en) * | 1991-11-29 | 2000-10-17 | Sunil Chada | Anti-cancer immunotherapeutic vector constructs |
US6297048B1 (en) | 1992-02-04 | 2001-10-02 | Chiron Corporation | Hepatitis therapeutics |
EP0729511A1 (en) | 1993-11-18 | 1996-09-04 | Chiron Corporation | Compositions and methods for utilizing conditionally lethal genes |
US5591625A (en) * | 1993-11-24 | 1997-01-07 | Case Western Reserve University | Transduced mesenchymal stem cells |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
EP0811057B1 (en) * | 1995-02-21 | 2006-04-26 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
DK0835137T3 (da) * | 1995-06-27 | 2006-03-06 | Bavarian Nordic As | Indkapslede celler, som danner viruspartikler |
US6136598A (en) * | 1997-05-09 | 2000-10-24 | Fred Hutchinson Cancer Research Center | Mus dunni endogenous retroviral packaging cell lines |
WO1998051369A1 (en) | 1997-05-13 | 1998-11-19 | Edwards Stuart D | Global medical treatment method and apparatus |
US5973119A (en) * | 1998-06-05 | 1999-10-26 | Amgen Inc. | Cyclin E genes and proteins |
ES2151403B1 (es) * | 1998-07-13 | 2001-07-01 | Hernandez Bronchud Miguel | Linea celular transformada de rata productora de tnf-alfa humano recombinante. |
US6344541B1 (en) * | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
AU3770800A (en) | 1999-03-26 | 2000-10-16 | Amgen, Inc. | Beta secretase genes and polypeptides |
AU5003200A (en) | 1999-05-14 | 2000-12-05 | United States Of America As Represented By The Department Of Veterans Affairs, The | Isolation and characterization of epidermal growth factor related protein |
US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
US7408047B1 (en) * | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6900043B1 (en) * | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
KR100630880B1 (ko) * | 1999-12-31 | 2006-10-02 | 엘지.필립스 엘시디 주식회사 | 엑스레이 영상 감지소자 및 그 제조방법 |
US20050239061A1 (en) * | 2000-03-01 | 2005-10-27 | Marshall William S | Identification and use of effectors and allosteric molecules for the alteration of gene expression |
US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
AU2001270266B2 (en) | 2000-06-28 | 2004-10-21 | Amgen Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
US20030031628A1 (en) * | 2001-07-09 | 2003-02-13 | Ming Zhao | Imaging infection using fluorescent protein as a marker |
AU2003217693A1 (en) * | 2002-02-22 | 2003-09-09 | Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
US7662924B2 (en) * | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
CN100434440C (zh) | 2002-12-02 | 2008-11-19 | 阿布格尼克斯公司 | 针对肿瘤坏死因子的抗体及其用途 |
EP2298896A1 (en) | 2004-06-22 | 2011-03-23 | The Board of Trustees of the University of Illinois | Methods of inhibiting tumor cell proliferation with FOXM1 siRNA |
WO2006086607A2 (en) * | 2005-02-10 | 2006-08-17 | Emory University | Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation |
WO2009018250A2 (en) * | 2007-07-30 | 2009-02-05 | University Of Iowa Research Foundation | Use of rpa4 and rpa4/rpa32 hybrid polypeptides for modulating cell proliferation |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
WO2010042747A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
SG10201707763PA (en) * | 2009-05-05 | 2017-11-29 | Amgen Inc | FGF21 Mutants And Uses Thereof |
JP2012530493A (ja) * | 2009-06-17 | 2012-12-06 | アムジエン・インコーポレーテツド | キメラポリペプチドおよびその使用 |
MX2012006397A (es) * | 2009-12-02 | 2012-11-30 | Amgen Inc | PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA. |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトFGF受容体およびβ−KLOTHO結合性タンパク質 |
EP3190187A1 (en) | 2010-05-21 | 2017-07-12 | Peptimed, Inc. | Reagents and methods for treating cancer |
WO2012095548A2 (es) | 2011-01-13 | 2012-07-19 | Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) | Compuestos para el tratamiento de enfermedades neurodegenerativas |
US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS605692Y2 (ja) * | 1977-06-02 | 1985-02-22 | 日本電気株式会社 | 宅内機器構造 |
JPS61922Y2 (es) * | 1979-12-17 | 1986-01-13 | ||
US4405712A (en) * | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4769330A (en) * | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
US4663281A (en) * | 1984-03-22 | 1987-05-05 | Mass Institute Of Technology | Enhanced production of proteinaceous materials in eucaryotic cells |
US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
WO1985005629A1 (en) * | 1984-05-25 | 1985-12-19 | Dana-Farber Cancer Institute | Ltr vectors, methods of preparation and use |
WO1985005618A1 (en) * | 1984-06-06 | 1985-12-19 | Takeda Chemical Industries, Ltd. | Process for preparing interferon derivative |
WO1986000922A1 (en) * | 1984-07-30 | 1986-02-13 | The Salk Institute For Biological Studies | Retroviral gene transfer vectors |
GB8424757D0 (en) * | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
US4677063A (en) * | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
FR2571737B1 (fr) * | 1984-10-15 | 1987-02-20 | Agronomique Inst Nat Rech | Vecteurs de clonage ou d'expression comportant le genome du virus de l'erythroblastose aviaire et cellules transfectees par ces vecteurs |
US4725669A (en) * | 1984-11-09 | 1988-02-16 | President And Fellows Of Harvard College | Assay for detecting infection by human T-cell lymphotropic virus-III |
US4839284A (en) * | 1985-05-16 | 1989-06-13 | New York University | Murine host-vector system capable of amplifying and expressing transfected genes |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
ATE68013T1 (de) * | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
AU3069189A (en) * | 1988-02-05 | 1989-08-25 | Trustees Of Columbia University In The City Of New York, The | Retroviral packaging cell lines and processes of using same |
-
1987
- 1987-04-21 CA CA000535154A patent/CA1310924C/en not_active Expired - Lifetime
- 1987-04-24 ES ES87303651T patent/ES2083353T3/es not_active Expired - Lifetime
- 1987-04-24 AT AT87303651T patent/ATE133449T1/de not_active IP Right Cessation
- 1987-04-24 EP EP87303651A patent/EP0243204B1/en not_active Expired - Lifetime
- 1987-04-24 DE DE3751682T patent/DE3751682T2/de not_active Expired - Fee Related
- 1987-04-24 JP JP62102979A patent/JP2773833B2/ja not_active Expired - Fee Related
-
1994
- 1994-11-29 US US08/346,361 patent/US5652130A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/467,553 patent/US5635399A/en not_active Expired - Lifetime
-
1996
- 1996-03-29 GR GR960400835T patent/GR3019460T3/el unknown
-
1997
- 1997-03-27 HK HK38497A patent/HK38497A/xx not_active IP Right Cessation
-
1998
- 1998-02-10 JP JP10028426A patent/JP2843318B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2843318B2 (ja) | 1999-01-06 |
HK38497A (en) | 1997-04-04 |
JPS63157985A (ja) | 1988-06-30 |
DE3751682T2 (de) | 1996-09-12 |
JP2773833B2 (ja) | 1998-07-09 |
DE3751682D1 (de) | 1996-03-07 |
EP0243204A3 (en) | 1989-02-22 |
US5652130A (en) | 1997-07-29 |
ATE133449T1 (de) | 1996-02-15 |
GR3019460T3 (en) | 1996-06-30 |
EP0243204B1 (en) | 1996-01-24 |
EP0243204A2 (en) | 1987-10-28 |
US5635399A (en) | 1997-06-03 |
CA1310924C (en) | 1992-12-01 |
JPH10287590A (ja) | 1998-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2083353T3 (es) | Sistema infectivo de liberacion de farmacos. | |
DE3880593D1 (de) | Arzneizubereitungen mit retardierter wirkstofffreisetzung. | |
ATE46080T1 (de) | Pharmazeutische komposition. | |
DK583789A (da) | System til transmucosal indgivelse af den aktive bestanddel af et laegemiddel | |
DE3784594D1 (de) | Mikrokapseln enthaltende pharmazeutische zusammensetzungen. | |
NO873534L (no) | Stabilt farmasoeytisk gelpreparat. | |
DE3863678D1 (de) | Lithiumsalze enthaltende pharmazeutische zubereitungen. | |
DE3770280D1 (de) | Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha. | |
DE3882157D1 (de) | Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen. | |
DE69119810D1 (de) | Pyrogensorbentmittel | |
ES2133295T3 (es) | Peptidos ciclicos y su uso. | |
NO883500L (no) | Fremgangsmaate for fremstilling av et farmasoeytisk aktivt nitrometan. | |
WO1991015512A3 (en) | Hiv envelope polypeptides | |
NO912142L (no) | Foradditiv til fisk. | |
DE68902300T2 (de) | Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. | |
DK0575432T3 (en) | Modified proteins and their use for controlling viral infections. | |
DE3873011D1 (de) | Pharmazeutische zusammensetzung, enthaltend piperidinalkanolderivate. | |
NO873514L (no) | Fremgangsmaate for fremstilling av farmasoeytisk aktive forbindelser. | |
DK229089A (da) | Peptid-laegemiddelpraeparater indeholdende alfa-aminoborsyrederivater til indgift via slimhinden | |
DE58905160D1 (de) | Pharmazeutische zubereitung. | |
DE3773322D1 (de) | Pharmazeutische zubereitungen mit heilender aktivitaet. | |
ATE64535T1 (de) | Xylometazolinhaltige pharmazeutische praeparate. | |
ATE104284T1 (de) | Pharmazeutische aktive verbindungen. | |
PT85350B (de) | Xylometazolinhaltige pharmazeutische praeparate | |
ATE78684T1 (de) | Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 243204 Country of ref document: ES |